Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: A phase II, open-label, uncontrolled trial in Japan

Microbiology and Immunology

Volumn 59, Issue 10, 2015, Pages 597-604

  Tsurudome, Yukari ^a   Kimachi, Kazuhiko ^a   Okada, Yusuke ^a   Matsuura, Kenta ^a   Ooyama, Yusuke ^a   Ibaragi, Kayo ^a   Kino, Yoichiro ^a   Ueda, Kohji ^b  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b Seinan Jo Gakuin University   (Japan)

Author keywords

Immunogenicity; Inactivated quadrivalent vaccine; Influenza; Safety

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTUSION; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROENTERITIS; GEOMETRY; HEADACHE; HEMAGGLUTINATION INHIBITION; HEMOLYSIS; HUMAN; IMMUNOGENICITY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; JAPAN; MALAISE; MALE; MASTALGIA; NONHUMAN; OPEN STUDY; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; RHINORRHEA; SEROCONVERSION; SINGLE DRUG DOSE; SPRAIN; TONSILLITIS; UPPER ABDOMINAL PAIN; VACCINATION; VIRUS STRAIN; ADVERSE DRUG REACTION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; NORMAL HUMAN; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; SEROCONVERSION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84944458391     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12316     Document Type: Article

References (32)

1. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. (1990) Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175: 59-68.
2. Ambrose C.S., Levin M.J. (2012) The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 8(1): 81-8.
3. National Institute of Infectious Diseases (NIID). (2010). Annual Report 2010 National Epidemiological Surveillance of Vaccine-Preventable Diseases. [Cited March 2010]. Available from URL: http://www.nih.go.jp/niid/images/epi/yosoku/AnnReport/2010-03.pdf (in Japanese).
4. IASR (Infectious Agents Surveillance Report), Infectious Surveillance Centre, NIID, Japan. Analysis of Influenza Strains Isolated during 2011-2012 Season. 33: 288-94 November 2012. [Cited November 2012] Available from URL: http://www.nih.go.jp/niid/ja/iasr-sp/2124-related-articles/related-articles-393.html?start=1 (in Japanese)
5. IASR (Infectious Agents Surveillance Report), Infectious Surveillance Centre, NIID, Japan. Analysis of Influenza Strains Isolated during 2012-2013 Season. 34: 328-34 November 2013 [Cited November 2013] Available from URL: http://www.nih.go.jp/niid/ja/iasr-sp/2257-related-articles/related-articles-405/4089-dj4051.html (in Japanese)
6. IASR (Infectious Agents Surveillance Report), Infectious Surveillance Centre, NIID, Japan. Analysis of Influenza Strains Isolated during 2013-2014 Season. 35: 254-8 November 2014 [Cited November 2014] Available from URL: http://www.nih.go.jp/niid/ja/iasr-sp/2301-related-articles/related-articles-417/5111-dj4171.html (in Japanese).
7. WHO. Recommended Composition of Influenza Virus Vaccines for Use in the 2012-2013 Northern Hemisphere Influenza Season. Available from URL: http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf.
8. WHO. Department of Communicable Disease Surveillance and Response. WHO Manual on Animal Influenza Diagnosis and Surveillance. May 2002. [Cited May 2002] Available from URL: http://www.wpro.who.int/emerging_diseases/documents/docs/manualonanimalaidiagnosisandsurveillance.pdf
9. Ikeno D., Kimachi K., Kino Y., Harada S., Yoshida K., Tochihara S., Itamura S., Odagiri T., Tashiro M., Okada K., Miyazaki C., Ueda K. (2010) Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 54: 81-8.
10. European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Harmonization of Requirements for Influenza Vaccines (CPMP/BWP/214/96). 12 March 1997. [Cited March 1997] Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
11. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., Lilac H.A., Hall H., Klimov A., Fukuda K. (2000) Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 284: 1655-63.
12. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., Lindstrom S., Shay D.K., Marshfield Influenza Study Group. (2009) Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199: 159-67.
13. Skowronski D.M., De Serres G., Dickinson J., Petric M., Mak A., Fonseca K., Kwindt T.L., Chan T., Bastien N., Charest H., Li Y. (2009) Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 199: 168-79.
14. Lo Y.C., Chuang J.H., Kuo H.W., Huang W.T., Hsu Y.F., Liu M.T., Chen C.H., Huang H.H., Chang C.H., Chou J.H., Chang F.Y., Lin T.Y., Chiu W.T. (2013) Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-2012 season. PLoS ONE 8: e58222.
15. Traynor K. (2012) First quadrivalent flu vaccine approved. Am J Health Syst Pharm 69: 538.
16. Block S.L., Yi T., Sheldon E., Dubovsky F., Falloon J. (2011) A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 29: 9391-7.
17. Kieninger D., Sheldon E., Lin W.Y., Yu C.J., Bayas J.M., Gabor J.J., Esen M., Fernandez Roure J.L., Narejos Perez S., Alvarez Sanchez C., Feng Y., Claeys C., Peeters M., Innis B.L., Jain V. (2013) Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 13: 343.
18. Tinoco J.C., Pavia-Ruz N., Cruz-Valdez A., Aranza Doniz C., Chandrasekaran V., Dewé W., Liu A., Innis B.L., Jain V.K. (2014) Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial. Vaccine 32: 1480-7.
19. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 31: 770-6.
20. Pépin S., Donazzolo Y., Jambrecina A., Salamand C., Saville M. (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 31: 5572-8.
21. Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi T., Belshe R.B. (2012) Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 31: 745-51.
22. Langley J.M., Carmona Martinez A., Chatterjee A., Halperin S.A., McNeil S., Reisinger K.S., Aggarwal N., Huang L.M., Peng C.T., Garcia-Sicilia J., Salamanca de la Cueva I., Cabañas F., Treviño-Garza C., Rodríguez-Weber M.A., de la O.M., Chandrasekaran V., Dewé W., Liu A., Innis B.L., Jain V.K. (2013) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: A phase III randomized controlled trial in children. J Infect Dis 208: 544-53.
23. Suryadevara M., Domachowske J.B. (2014) Quadrivalent influenza vaccine in the United States. Hum Vaccin Immunother 10(3): 596-9.
24. Reed C., Meltzer M.I., Finelli L., Fiore A. (2012) Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30: 1993-8.
25. Clements K.M., Meier G., McGarry L.J., Pruttivarasin N., Misurski D.A. (2014) Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 10: 1171-80.
26. Newall A.T., Dehollain J.P. (2014) The cost-effectiveness of influenza vaccination in elderly Australians: An exploratory analysis of the vaccine efficacy required. Vaccine 32: 1323-5.
27. Van Bellinghen L.A., Meier G., Van Vlaenderen I. (2014) The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: A lifetime multi-cohort model. PLoS ONE 9: e98437.
28. You J.H., Ming W.K., Chan P.K. (2015) Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong-a decision analysis. Hum Vaccin Immunother 11: 564-71.
29. Meier G., Gregg M., Poulsen Nautrup B. (2015) Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: An updated analysis in the United Kingdom. J Med Econ 1: 1-16.
30. Odagiri T. (2012) Strain selection process of and problems in influenza vaccines: Future perspectives of improvement. Pediatr Jpn 53: 1355-65 (in Japanese).
31. Walter E.B., Neuzil K.M., Zhu Y., Fairchok M.P., Gagliano M.E., Monto A.S., Englund J.A. (2006) Influenza vaccine immunogenicity in 6- to 23-month-old children: Are identical antigens necessary for priming? Pediatrics 118: e570-8.
32. Skowronski D.M., Hottes T.S., De Serres G., Ward B.J., Janjua N.Z., Sabaiduc S., Chan T., Petric M. (2011) Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J 30: 833-9.